Archives

FS KKR Capital Corp. Announces First Quarter 2026 Results and Strategic Value Enhancement Actions; Declares Second Quarter 2026 Distribution of $0.42 per share

B PHILADELPHIA and NEW YORK, May 11, 2026 /PRNewswire/ — FS KKR Capital Corp. (NYSE: FSK), or the Company, today announced its financial and operating results… Login to continue reading Login…

Read MoreFS KKR Capital Corp. Announces First Quarter 2026 Results and Strategic Value Enhancement Actions; Declares Second Quarter 2026 Distribution of $0.42 per share

Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher

B First Targeted Therapy Approved for NRG1+ Cholangiocarcinoma BIZENGRI Now Approved for Patients Harboring NRG1 Gene Fusions in Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, and… Login to continue reading Login…

Read MorePartner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher